There are 93 papers on FGF23 in aging research: 4 trials and 34 observational studies in people, 21 in animals, 30 reviews.
At a glance
The findings reach people, from one lab or study. 12 independent labs in 9 countries; 4 trials, 3 with no results posted.
“In both cohorts, FGF23 associated negatively with high-density lipoprotein and apolipoprotein A1 (7% to 21% decrease per 1-SD increase in log FGF23; P<0.01)”
None of its findings points the other way.
- 12 independent labs in 9 countries
- 4 trials, 3 with no results posted
- Funders: National Institute of Diabetes and Digestive and Kidney Diseases and others
- 4 of 4 trials sponsored by developers of drugs aimed at it
- Human trial4
- Humans34
- Animals21
- In silico1
Interventions
2Glucagon-like peptide-2
downin mice1
1 study
Glucagon-like peptide-2
downin mice1
Glucagon-like peptide-2 decreases FGF23 in ovariectomized mice.
“upregulated Runx2 expression, and downregulated FGF23 expression.”
Animalsin ovariectomized micebone
Journal of orthopaedic surgery and research
Coenzyme Q10 + selenium
downin humans1
1 study
Coenzyme Q10 + selenium
downin humans1
Coenzyme Q10 + selenium decreases FGF23 in humans (p = 0.01).
“Following supplementation with selenium and coenzyme Q10, a significantly lower level of FGF-23 could be seen (p = 0.01).”
Human trial48 monthsn = 219
Cells
Effects
13Phosphate excretion
upin reviews2
2 studies
Phosphate excretion
upin reviews2
FGF23 increases phosphate excretion (through the αKlotho-FGF23 signaling axis).
“Through the αKlotho-FGF23 signaling axis, FGF23 regulates phosphate excretion by downregulating Na+-dependent phosphate transporter (NaPi-2a).”
Reviewthrough the αKlotho-FGF23 signaling axis
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
FGF23 induces phosphate excretion.
“a bone-derived hormone that induces phosphate excretion into urine”
Review
Pflugers Archiv : European journal of physiology
Coronary artery calcification
mediatesin silico1
1 study
Coronary artery calcification
mediatesin silico1
FGF23 mediates coronary artery calcification in PCSK9-CAC axis (mediated effect=0.024; mediation proportion=13.86%).
“Mediation MR analysis suggested FGF23 as a partial mediator in the PCSK9-CAC axis (mediated effect=0.024; mediation proportion=13.86%).”
In silicoin PCSK9-CAC axis
Frontiers in cardiovascular medicine
Bone loss
no changein mice1
1 study
Bone loss
no changein mice1
FGF23 showed no clear effect on bone loss in mice.
“Global knockout of Fgf23 in Fgf23/VDR compound mutants did not rescue the TAC-induced skeletal phenotype.”
Animalsshown by global Fgf23 knockout in Fgf23/VDR compound mutants after transverse aortic constriction4 and 6 weeks
International journal of molecular sciences
Left ventricular hypertrophy
upin reviews1
1 study
Left ventricular hypertrophy
upin reviews1
FGF23 induces left ventricular hypertrophy in CKD.
“Moreover, FGF23 directly induces left ventricular hypertrophy (LVH) through FGF receptor-induced calcineurin/nuclear factor of activated T cells (NFAT) signaling in CKD.”
Reviewin CKD
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
Handgrip strength
upin humans1
1 study
Handgrip strength
upin humans1
FGF23 is linked with better handgrip strength in humans (maintenance hemodialysis) (beta = 5.39, 95% CI 2.07-8.72).
“in multiple regression analyses, it was found to be a significant independent predictor of both handgrip strength (beta = 5.39, 95% CI 2.07-8.72)”
Humansmaintenance hemodialysisserumn = 81
Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population
Journal of cachexia, sarcopenia and muscle
Longevity
no changein humans1
1 study
Longevity
no changein humans1
FGF23 was not clearly linked with longevity in humans.
“but not with the other outcomes”
Humans
Frontiers in genetics
1,25(OH)2D
downin mice1
1 study
1,25(OH)2D
downin mice1
FGF23 decreases 1,25(OH)2D in mice (elevated FGF23).
“Elevated FGF23 suppressed 1,25(OH)2D and parathyroid hormone levels”
Animalselevated FGF23
FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model
JCI insight
Phosphate reabsorption
downin reviews1
1 study
Phosphate reabsorption
downin reviews1
FGF23 decreases phosphate reabsorption.
“Fibroblast growth factor-23 (FGF23) is a bone-derived hormone known to suppress phosphate reabsorption and vitamin D hormone production in the kidney.”
Reviewkidney
Update on FGF23 and Klotho signaling
Molecular and cellular endocrinology
CYP27B1
downin mice1
1 study
CYP27B1
downin mice1
FGF23 decreases CYP27B1 in Fgf-23(-/-) /hFGF-23-Tg double mutants vs Fgf-23(-/-) mice.
“These changes were associated with reduced renal expression of NaPi2a and 1 alpha-hydroxylase, compared to Fgf-23(-/-) mice.”
Animalsin Fgf-23(-/-) /hFGF-23-Tg double mutants vs Fgf-23(-/-) micekidney
The Journal of pathology
SLC34A1
downin mice1
1 study
SLC34A1
downin mice1
FGF23 decreases SLC34A1 in Fgf-23(-/-) /hFGF-23-Tg double mutants vs Fgf-23(-/-) mice.
“These changes were associated with reduced renal expression of NaPi2a and 1 alpha-hydroxylase, compared to Fgf-23(-/-) mice.”
Animalsin Fgf-23(-/-) /hFGF-23-Tg double mutants vs Fgf-23(-/-) micekidney
The Journal of pathology
All 13Fewer
Upstream
2FOXO1
upin mouse cells1
1 study
FOXO1
upin mouse cells1
FOXO1 increases FGF23 in mouse cells.
“Inhibition of FOXO1 can reduce FGF23 expression, whereas the overexpression of FOXO1 leads to an increase in FGF23 expression”
Cellsosteoblasts
Journal of orthopaedic surgery and research
Cellular senescence
upin mouse cells1
1 study
Cellular senescence
upin mouse cells1
Cellular senescence increases FGF23 in mouse cells (senescence induced in MLO-Y4 cells).
“senescence induction in MLO-Y4 cells increased the Fgf23 and Sost mRNA expression.”
Cellssenescence induced in MLO-Y4 cells
SIRT6-PAI-1 axis is a promising therapeutic target in aging-related bone metabolic disruption
Scientific reports
Associations
14Abdominal aortic calcification
upin silico1OR 1.082
1 study
Abdominal aortic calcification
upin silico1OR 1.082
FGF23 raises the risk of abdominal aortic calcification in silico (OR 1.082, 95% CI 1.016-1.151).
“Univariable MR analysis suggested a modest association between genetically predicted circulating FGF23 levels and a higher risk of AAC (odds ratio = 1.082, 95% confidence interval = 1.016-1.151, P = .013).”
In silico
Medicine
Capillary diameter
upin humans1
1 study
Capillary diameter
upin humans1
FGF23 is associated with capillary diameter in humans (chronic kidney disease).
“fibroblast growth factor 23 levels were positively related to capillary diameter”
Humanschronic kidney diseasen = 96
Evaluation of Endothelial Dysfunction in Geriatric Patients with Non-Dialysis Chronic Kidney Disease
Journal of clinical medicine
eGFR slope
downin humans1
1 study
eGFR slope
downin humans1
FGF23 is associated with eGFR slope in humans (unadjusted/baseline correlation).
“Higher baseline ePTFp and serum FGF23 were inversely correlated with eGFR slope.”
Humansunadjusted/baseline correlation5 yearsn = 308
Clinical kidney journal
Sarcopenia
downin humans1OR 0.14
1 study
Sarcopenia
downin humans1OR 0.14
FGF23 is linked with a lower risk of sarcopenia in humans (maintenance hemodialysis) (OR 0.14, 95% CI 0.02-0.75).
“in multiple regression analyses, it was found to be a significant independent predictor of both handgrip strength (beta = 5.39, 95% CI 2.07-8.72) and sarcopenia (odds ratio = 0.14, 95% CI 0.02-0.75).”
Humansmaintenance hemodialysisserumn = 81
Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population
Journal of cachexia, sarcopenia and muscle
Frozen shoulder
upin humans1OR 1.2424
1 study
Frozen shoulder
upin humans1OR 1.2424
FGF23 is linked with a higher risk of frozen shoulder in humans (OR 1.2424, P = 0.0316).
“fibroblast growth factor-23 (FGF-23) impacted frozen shoulder (FS) (OR 1.2424, P = 0.0316)”
Humans
Experimental gerontology
Arterial embolism and thrombosis
upin humans1OR 1.661
1 study
Arterial embolism and thrombosis
upin humans1OR 1.661
FGF23 is linked with a higher risk of arterial embolism and thrombosis in humans (OR 1.661, 95% CI 1.051-2.624).
“Causality was also identified between the genetically predicted levels of FGF23 and other arterial embolism and thrombosis (IVW: OR: 1.661, 95% CI 1.051-2.624, P = 0.029)”
Humans
Clinical epigenetics
Calcific aortic valve stenosis
upin silico1
1 study
Calcific aortic valve stenosis
upin silico1
FGF23 raises the risk of calcific aortic valve stenosis in silico.
“genetic mimicry of serum FGF23 elevation was associated with increased CAVS risk”
In silico
NPJ cardiovascular health
Type 2 diabetes
downin humans1OR 0.7
1 study
Type 2 diabetes
downin humans1OR 0.7
FGF23 is linked with a lower risk of type 2 diabetes in humans (OR 0.70 (95% CI: 0.52-0.96)).
“type 2 diabetes mellitus (T2DM) (OR: 0.70, 95% CI: 0.52-0.96)”
Humans
Frontiers in genetics
Coronary artery disease
downin humans1OR 0.69
1 study
Coronary artery disease
downin humans1OR 0.69
FGF23 is linked with a lower risk of coronary artery disease in humans (OR 0.69 (95% CI: 0.52-0.91) per log-transformed pg/ml increase).
“genetically predicted higher FGF23 was inversely associated with risk of CAD [odds ratio (OR): 0.69 per logtransformed FGF23 (pg/ml) increase, 95% confidence interval (CI): 0.52-0.91]”
Humans
Frontiers in genetics
Cardiovascular function
mixedin reviews1
1 study
Cardiovascular function
mixedin reviews1
FGF23 is associated with cardiovascular function.
“FGF23 has emerged as a pleiotropic endocrine and auto-/paracrine factor influencing not only mineral metabolism but also cardiovascular function.”
Reviewcardiovascular system
Update on FGF23 and Klotho signaling
Molecular and cellular endocrinology
All 14Fewer
Funding
4 grants since 2018National Institute of Diabetes and Digestive and Kidney Diseases$3MJapan Society for the Promotion of Science¥17.3MNational Institute on Aging$3.1M
National Institute on AgingIndiana University Indianapolis$3.1M2025–2029
Role of FGF23 and Phosphate in Chronic Kidney Disease
National Institute of Diabetes and Digestive and Kidney DiseasesNorthwestern University$559K2022–2026
Functional roles of FGF23/alpha-Klotho system in the regulation of aging in the hypothalamus
Japan Society for the Promotion of ScienceWakayama Medical University¥17.3M2019–2022
Impact of phosphate and FGF23 reduction on intermediate end points in CKD
National Institute of Diabetes and Digestive and Kidney DiseasesNorthwestern University$593K2014–2020